225220.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 0.35, indicating a relatively conservative leverage position. However, the company's liquidity is assessed as medium, with a current ratio of 1.3, suggesting limited short-term liquidity cushion. The company's price-to-book ratio is 0.48, and the price-to-tangible-book ratio is also 0.48, indicating that the market values the company's tangible assets at a discount to their book value. The enterprise value to revenue ratio is 4.02, and the enterprise value to EBITDA ratio is -3.51, reflecting the company's current unprofitability.

Profitability metrics show the company is unprofitable, with a return on equity of -17.02% and a return on assets of -12.41%. These figures are significantly below the industry median for biotechnology and medical research firms, which typically exhibit positive returns on equity and assets. The company's operating margin is negative, and its net margin is also negative, indicating that the company is not generating sufficient revenue to cover its operating and non-operating expenses.

The company's revenue is not segmented by geographic region or business segment in the available data, making it difficult to assess geographic or product concentration risk. However, the company's revenue is entirely derived from its operations in the biotechnology and medical research sector, which is subject to high volatility and regulatory scrutiny.

The company's growth trajectory is uncertain, with no specific revenue growth or decline projections provided in the available data. The company's operating cash flow is negative, and its free cash flow is also negative, indicating that the company is not generating sufficient cash from operations to fund its capital expenditures or to service its debt. The company's capital expenditures are relatively small compared to its operating cash flow, suggesting that the company is not investing heavily in new projects or expansion.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations or invest in growth opportunities. The company's dilution risk is assessed as low, suggesting that there is little immediate threat of share dilution from new equity issuances or convertible securities. The company's valuation adjustments do not indicate any significant changes to its financial position.

Recent events and filings do not provide specific details on the company's operations or financial performance. The company's latest actual revenue is reported at 1.5 billion KRW, which is significantly lower than its reported revenue of 9.4 billion KRW. This discrepancy may indicate a need for further investigation into the company's financial reporting practices or market conditions affecting its revenue.